Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

2019430 citationsJournal Articlehybrid Open Access

Authors

Jhanelle E. Gray · Moffitt Cancer Center

Augusto Villegas · Florida Cancer Specialists & Research Institute

Davey B. Daniel · Tennessee Oncology

David Vicente · Hospital Universitario Virgen Macarena

Shuji Murakami · Kanagawa Prefectural Hospital Organization

Rina Hui · The University of Sydney

Takayasu Kurata

Abstract

Updated OS data from PACIFIC, including 3-year survival rates, demonstrate the long-term clinical benefit with durvalumab after chemoradiotherapy and further establish the PACIFIC regimen as the standard of care in this population.

Topics & Keywords

Esophageal Cancer Research and Treatment Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Thoracic Oncology

Volume 15, Issue 2, pp. 288-293

DOI: 10.1016/j.jtho.2019.10.002

Field-Weighted Citation Impact: 66.03